<DOC>
	<DOC>NCT00750620</DOC>
	<brief_summary>The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.</brief_summary>
	<brief_title>A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>good health other than renal impairment body mass index (BMI) between 18 and 40 kg/m2 subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks subject has liver enzyme abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>mild, moderate, and severe renal impaired subjects</keyword>
	<keyword>normal renal function subjects</keyword>
	<keyword>Glomerular filtration rate (GFR)</keyword>
	<keyword>Modification of Diet in Renal Disease (MDRD) formula</keyword>
	<keyword>YM178</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>